These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7739293)

  • 1. Inhibitors of phospholipid intracellular signaling as antiproliferative agents.
    Powis G; Hill SR; Frew TJ; Sherrill KW
    Med Res Rev; 1995 Mar; 15(2):121-38. PubMed ID: 7739293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signalling pathways as targets for anticancer drug development.
    Powis G
    Pharmacol Ther; 1994; 62(1-2):57-95. PubMed ID: 7991648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs active against growth factor and oncogene phosphatidylinositol signalling pathways.
    Powis G
    Semin Cancer Biol; 1992 Dec; 3(6):343-50. PubMed ID: 1286155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of phosphatidylinositol signalling as antiproliferative agents.
    Powis G; Phil D
    Cancer Metastasis Rev; 1994 Mar; 13(1):91-103. PubMed ID: 8143348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth factor and oncogene signalling pathways as targets for rational anticancer drug development.
    Powis G; Kozikowski A
    Clin Biochem; 1991 Oct; 24(5):385-97. PubMed ID: 1760877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
    Fabbro D; Ruetz S; Buchdunger E; Cowan-Jacob SW; Fendrich G; Liebetanz J; Mestan J; O'Reilly T; Traxler P; Chaudhuri B; Fretz H; Zimmermann J; Meyer T; Caravatti G; Furet P; Manley PW
    Pharmacol Ther; 2002; 93(2-3):79-98. PubMed ID: 12191602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases.
    Zhang Z; Li M; Rayburn ER; Hill DL; Zhang R; Wang H
    Am J Pharmacogenomics; 2005; 5(3):173-90. PubMed ID: 15952871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signalling targets for anticancer drug development.
    Powis G
    Trends Pharmacol Sci; 1991 May; 12(5):188-94. PubMed ID: 1862534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cell membrane and cell signals: new targets for novel anticancer drugs.
    Workman P
    Ann Oncol; 1990; 1(2):100-11. PubMed ID: 1706612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach.
    Favoni RE; de Cupis A
    Pharmacol Rev; 2000 Jun; 52(2):179-206. PubMed ID: 10835099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signal transduction pathways: new targets in oncology.
    Sweeb RK; Beijnen JH
    Pharm World Sci; 1993 Dec; 15(6):233-42. PubMed ID: 8298582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular signalling as a target in cancer chemotherapy. Phospholipid analogues as inhibitors of mitogenic signal transduction.
    Grunicke HH; Maly K; Uberall F; Schubert C; Kindler E; Stekar J; Brachwitz H
    Adv Enzyme Regul; 1996; 36():385-407. PubMed ID: 8869757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.
    Cepero V; Sierra JR; Giordano S
    Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
    Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M
    Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report of a meeting: molecular basis of cancer therapy.
    Gottesman MM
    J Natl Cancer Inst; 1994 Sep; 86(17):1277-85. PubMed ID: 7914937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein-tyrosine kinases: potential targets for anticancer drug development.
    Burke TR
    Stem Cells; 1994 Jan; 12(1):1-6. PubMed ID: 7511455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.